Abstract
TNK1 is a non-receptor tyrosine kinase with poorly understood biological function and regulation. Here, we identify TNK1 dependencies in primary human cancers. We also discover a MARK-mediated phosphorylation on TNK1 at S502 that promotes an interaction between TNK1 and 14-3-3, which sequesters TNK1 and inhibits its kinase activity. Conversely, the release of TNK1 from 14-3-3 allows TNK1 to cluster in ubiquitin-rich puncta and become active. Active TNK1 induces growth factor-independent proliferation of lymphoid cells in cell culture and mouse models. One unusual feature of TNK1 is a ubiquitin-association domain (UBA) on its C-terminus. Here, we characterize the TNK1 UBA, which has high affinity for poly-ubiquitin. Point mutations that disrupt ubiquitin binding inhibit TNK1 activity. These data suggest a mechanism in which TNK1 toggles between 14-3-3-bound (inactive) and ubiquitin-bound (active) states. Finally, we identify a TNK1 inhibitor, TP-5801, which shows nanomolar potency against TNK1-transformed cells and suppresses tumor growth in vivo.
© 2021. The Author(s).
Publication types
-
Research Support, N.I.H., Extramural
-
Research Support, Non-U.S. Gov't
MeSH terms
-
14-3-3 Proteins / genetics*
-
14-3-3 Proteins / metabolism
-
A549 Cells
-
Animals
-
Antineoplastic Agents / pharmacology
-
Cell Line, Tumor
-
Fetal Proteins / antagonists & inhibitors
-
Fetal Proteins / genetics*
-
Fetal Proteins / metabolism
-
Fusion Proteins, bcr-abl / genetics
-
Fusion Proteins, bcr-abl / metabolism
-
Gene Expression Regulation, Neoplastic
-
HEK293 Cells
-
Humans
-
Lymphocytes / drug effects
-
Lymphocytes / metabolism*
-
Lymphocytes / pathology
-
Mice
-
Phospholipase C gamma / genetics
-
Phospholipase C gamma / metabolism
-
Precursor B-Cell Lymphoblastic Leukemia-Lymphoma / drug therapy
-
Precursor B-Cell Lymphoblastic Leukemia-Lymphoma / genetics*
-
Precursor B-Cell Lymphoblastic Leukemia-Lymphoma / mortality
-
Precursor B-Cell Lymphoblastic Leukemia-Lymphoma / pathology
-
Protein Binding
-
Protein Kinase Inhibitors / pharmacology
-
Protein-Tyrosine Kinases / antagonists & inhibitors
-
Protein-Tyrosine Kinases / genetics*
-
Protein-Tyrosine Kinases / metabolism
-
Pyrimidines / pharmacology
-
STAT3 Transcription Factor / genetics
-
STAT3 Transcription Factor / metabolism
-
STAT5 Transcription Factor / genetics
-
STAT5 Transcription Factor / metabolism
-
Signal Transduction
-
Survival Analysis
-
Tumor Burden / drug effects
-
Ubiquitin / genetics*
-
Ubiquitin / metabolism
-
Xenograft Model Antitumor Assays
Substances
-
14-3-3 Proteins
-
Antineoplastic Agents
-
Fetal Proteins
-
Protein Kinase Inhibitors
-
Pyrimidines
-
STAT3 Transcription Factor
-
STAT3 protein, human
-
STAT5 Transcription Factor
-
Ubiquitin
-
Protein-Tyrosine Kinases
-
Fusion Proteins, bcr-abl
-
TNK1 protein, human
-
Phospholipase C gamma